ArticleScience progress
Analysis signals of disproportionate reporting associated with donanemab: A retrospective pharmacovigilance study using the FAERS database.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study aims to identify signals of disproportionate reporting (SDR) associated with donanemab by analyzing data from the Food and Drug Administration's Adverse Event Reporting System (FAERS) database.MethodsA retrospective analysis was conducted on reports related to donanemab in the FAERS database from the third quarter of 2024 to the second quarter of 2025. Four signal detection methods were employed: reporting odds ratio (ROR), proportional reporting ratio (PRR), Multi-item gamma poisson shrinkage (MGPS), and Bayesian confidence propagation neural network (BCPNN). Additionally, descriptive analysis was performed on the time to onset of reports associated with donanemab.ResultsA total of 646 reports identified donanemab as the primary suspect drug. We identified common SDRs listed on the drug label, including amyloid related imaging abnormality-oedema/effusion, amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits, headache, and infusion-related reactions. In addition, some SDRs not previously listed on the drug label, such as back pain, feeling hot, and influenza like illness, were also detected. The median time to onset for donanemab-related adverse events was 31.5 days (interquartile range: 25-58 days).ConclusionThis study provides a comprehensive analysis of SDRs associated with donanemab. These results are merely statistical indicators and require further validation through clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.